PubMed full publication listing. More recent publications are listed below.

Mantis Laboratory

Dulal HP, Vance DJ, Neupane DP, Chen X, Tremblay JM, Shoemaker CB, Mantis NJ, Song J. Neutralization of Typhoid Toxin by Alpaca-Derived, Single-Domain Antibodies Targeting the PltB and CdtB Subunits. Infect Immun. 2022; 90 (2): e0051521. DOI: 10.1128/IAI.00515-21
Peterson-Reynolds C, Mantis NJ. Differential ER stress as a driver of cell fate following ricin toxin exposure. FASEB Bioadv. 2021; 4 (1): 60-75. DOI: 10.1096/fba.2021-00005
Novak H, Doering J, Ehrbar D, Donini O, Mantis NJ. Durable Immunity to Ricin Toxin Elicited by a Thermostable, Lyophilized Subunit Vaccine. mSphere. 2021; 6 (6): e0075021. DOI: 10.1128/mSphere.00750-21
Richards A, Baranova D, Mantis NJ. The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections. Hum Vaccin Immunother. 2021; (7): 1-8. DOI: 10.1080/21645515.2021.1964317
Richards AF, Baranova DE, Pizzuto MS, Jaconi S, Willsey GG, Torres-Velez FJ, Doering JE, Benigni F, Corti D, Mantis NJ. Recombinant Human Secretory IgA Induces Salmonella Typhimurium Agglutination and Limits Bacterial Invasion into Gut-Associated Lymphoid Tissues. ACS Infect Dis. 2021; 7 (5): 1221-1235. DOI: 10.1021/acsinfecdis.0c00842
Ahn C, Yang YA, Neupane DP, Nguyen T, Richards AF, Sim JH, Mantis NJ, Song J. Mechanisms of typhoid toxin neutralization by antibodies targeting glycan receptor binding and nuclease subunits. iScience. 2021; 24 (5): 102454. DOI: 10.1016/j.isci.2021.102454
Czajka TF, Vance DJ, Mantis NJ. Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time. Trends Microbiol. 2021; 29 (3): 195-203. DOI: 10.1016/j.tim.2020.12.006
Vance DJ, Poon AY, Mantis NJ. Sites of vulnerability on ricin B chain revealed through epitope mapping of toxin-neutralizing monoclonal antibodies. PLoS One. 2020; 15 (11): e0236538. DOI: 10.1371/journal.pone.0236538
Baranova DE, Willsey GG, Levinson KJ, Smith C, Wade J, Mantis NJ. Transcriptional profiling of Vibrio cholerae O1 following exposure to human anti- lipopolysaccharide monoclonal antibodies. Pathog Dis. 2020; 78 (4): ftaa029. DOI: 10.1093/femspd/ftaa029